Shares of Metropolis Healthcare traded higher in Monday’s session after the diagnostics company reported a strong business performance for the December quarter of FY26.
Metropolis Healthcare shares were trading at Rs 1,960, up 3.33%, gaining Rs 63.20 on the NSE.
What drove the stock move
The uptick in the stock followed the company’s Q3 FY26 business update, where Metropolis reported around 26% year-on-year growth in consolidated revenue, driven by robust demand in preventive wellness tests and specialty diagnostics.
The company said growth during the quarter was supported by strong traction in its TruHealth wellness portfolio, higher volumes in specialty testing, and continued momentum across both B2C and B2B channels. Specialty testing revenues rose sharply, aided by an improved test mix and higher wallet share from customers.
Acquisitions and operational performance
Metropolis also highlighted steady progress in the integration of its recent acquisitions, including Core Diagnostics, Scientific Pathology (Agra), Dr. Ahuja’s Pathology & Imaging Center (Dehradun), and Ambika Pathology (Kolhapur). These acquisitions contributed positively to operational efficiency and margins during the quarter.
On a standalone basis, the company reported double-digit revenue growth, supported by higher patient footfalls, improved realization per patient, and expansion of its specialty test offerings.
The management noted that EBITDA margins improved year-on-year, despite the December quarter being seasonally softer for the diagnostics industry.
Metropolis clarified that the update is a business performance snapshot, with detailed audited financial results for Q3 FY26 to be announced separately after board approval.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
